### Toward Precision Medicine in Aortopathies: Genetic Insights from a Brazilian Cohort 1

- 2 **Through Targeted Next-Generation Sequencing**
- 3
- Juliana R. Ferreira,<sup>1</sup> Julia P. Perreira,<sup>1</sup> Anna Paula A. Botelho,<sup>1</sup> Daniele N. Aprijo,<sup>2</sup> Marcelo 4 M. Melo,<sup>1</sup> Helena C. V. Rey,<sup>1</sup> Glauber M Dias<sup>2</sup> 5
- 6
- 7 1- Instituto Nacional de Cardiologia, Rio de Janeiro, RJ, zip code 22240-002, Brazil
- 2- Laboratório de Biologia Celular e Tecidual, Universidade Estadual do Norte Fluminense 8
- Darcy Ribeiro, Campos dos Goytacazes, RJ, zip code 28013-602, Brazil. 9
- 10

### **Corresponding author:** 11

Glauber M Dias 12

glauber@uenf.br 13

14

### 15 ABSTRACT

16

Thoracic aortic diseases (or aortopathies) result from complex interactions between genetic 17 and hemodynamic factors. Often clinically silent, these diseases can lead to lethal 18 19 complications like aortic dissection or rupture. This study focused on a Brazilian cohort of 79 20 individuals with thoracic aortic diseases, exploring genetic factors through targeted nextgeneration sequencing (tNGS) of 15 priority genes. The majority of individuals had non-21 syndromic aortopathy, with eight diagnosed with Marfan syndrome (MFS). Pathogenic or 22 likely pathogenic variants (PV/LPV) were found in five genes, including FBN1, ACTA2, 23 TGFBR2, MYLK, and SMAD3. Notably, novel variants in FBN1 were identified, contributing 24 25 to Marfan-like phenotypes. The diagnostic yield for isolated aortopathies was 7.1%, rising to 26 55.5% for syndromic cases. Variants of uncertain significance (VUS) were identified, emphasizing the need for further research and familial investigations to refine variant 27 classifications. This study provides valuable insights into the genetic landscape of 28 29 aortopathies in Brazil, aiding early diagnosis and personalized management.

- 30
- 31

Keywords: Aortic Aneurysm Thoracic, Fibrilin-1, Aneurism dissecting, Genetic testing, High-32 Throughput nucleotide sequencing 33

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 34 INTRODUCTION

35

Aortopathies are diseases that affect the aortic artery and can occur either as an 36 isolated characteristic or as part of a syndromic condition. Their development is linked to a 37 complex interplay of genetic and hemodynamic factors. It is a clinically silent disease with a 38 natural history of lethality, progressing to aortic dissection or rupture, where half of the 39 patients die before reaching emergency services (1,2). The Centers for Disease Control and 40 Prevention (CDC) reports that aortic aneurysms (thoracic and abdominal) are the 15th 41 leading cause of death in individuals over 55 years old and the 19th leading cause of death 42 overall (3). In Brazil, we can observe that the average annual mortality was 12,820 deaths 43 due to aortic diseases, with a total of 128,204 deaths in the last 10 years and a mortality rate 44 of 5.89 (4). 45

Thoracic aorta diseases (TAD) can be associated with inherited genetic alterations. 46 whereas those affecting the abdominal aorta are more commonly of degenerative origin and 47 related to age and/or risk factors such as hypertension, smoking, dyslipidemia, and gender 48 (5). Hereditary thoracic aortic diseases (HTAD) are characterized by progressive 49 50 enlargement of the ascending aorta that predisposes to acute dissections (familial thoracic 51 aortic aneurisms /dissections) (6). HTAD can be divided into syndromic and non-syndromic types. Among syndromic TADs, Marfan syndrome (MFS) is the primary type, followed by 52 Loeys-Dietz syndrome (LDS) and Ehlers-Danlos syndrome (EDS), as well as other rarer 53 conditions (7). However, these syndromes contribute to only approximately 5% of all TAD 54 cases, while non-syndromic thoracic aortic diseases (NS-TAD) account for 95% of cases and 55 are further divided into sporadic and familial forms (8). 56

The genetic factors associated with TADs are inherited as monogenic mutations with 57 an autosomal dominant inheritance pattern (9). Detection of a pathogenic mutation is useful 58 for identifying an individual at risk of a potentially lethal aortic acute event (10). The known 59 genes implicated in this process encode members of the TGF $\beta$  signaling pathway (TGFBR1, 60 TGFBR2, TGFB2, SMAD3), components of the aortic wall extracellular matrix's structure and 61 integrity (FBN1, COL3A1, LOX); or those affecting the function of smooth muscle cells, 62 including actin (ACTA2), myosin (MYH11), myosin light chain kinase (MYLK), and protein 63 64 kinase cGMP-dependent 1 (PRKG1) (11,12).

65 The priority genes for TAD can be used to target research and diagnostic panels for aortopathies (13). However, for NS-TADs, the detection rate of variants in these genes is 66 67 approximately 20-30% (7,10), suggesting the involvement of other mechanisms (genetic or non-genetic) in the pathophysiology. In Brazil, the frequency or incidence of variants in NS-68 TADs is unknown. We selected a cohort of 79 individuals with isolated and syndromic TADs 69 70 from Brazil for genetic evaluation through NGS using a targeted gene panel. Here, we report the findings of the genetic screening of a Brazilian cohort of aortopathies. 71

72

#### 74 SUBJECTS AND METHODS

75

#### 76 Study Population:

77

78 Patients diagnosed with thoracic aortic aneurysm (TAA), aortic dissection, and aortic 79 coarctation before the age of 60, who were under the care of a guaternary cardiology center 80 in Brazil, were recruited for this study. Inclusion criteria encompassed patients with 81 suspected or confirmed clinical diagnosis of syndromic and non-syndromic aortopathies, all 82 of whom were below 60 years of age (y) at the time of diagnosis. Patients with or without a family history of aortopathies, as well as those clinically suspected of having MFS, LDS and 83 EDS were considered. Exclusion criteria included other causes of aortopathies such as 84 familial dyslipidemia, syphilis, autoimmune and inflammatory diseases, and trauma. A total of 85 358 patients were evaluated, out of which 103 met the inclusion criteria. After assessing the 86 exclusion criteria, 24 patients were excluded, leaving 79 participants for the study. 87

88

#### 89 Data Collection:

90

91 Data collection involved retrospective and prospective evaluation of patients from the date of diagnosis until December 2021. Patients were monitored for the occurrence of aortopathy-92 related complications (acute aortic syndrome, indication for aortic surgery) and mortality. 93

94

95

# Ethical Approval and Informed Consent:

96

97 This study received approval from the National Institute of Cardiology Research Ethics Committee (CAAE18868119.5.0000.5272), and all patients provided written informed 98 99 consent.

100

### 101 Genetic analysis

102

103 Genetic analysis of NS-TAD patients was performed by targeted next-generation 104 sequencing (tNGS) using a panel of 15 priority genes associated with aortic diseases (ACTA2, COL3A1, FBN1, LOX, MFAP5, MYH11, MYLK, PRKG1, SMAD3, TGFB2, 105 TGFBR1, TGFBR2, EFEMP2, SMAD2, FOXE3) (13). Sequencing was performed using 106 107 an Ion Torrent PGM platform (Thermo Fisher Scientific).

Patients with clinical diagnosis (or suspect) of SMF were evaluated by direct 108 sequencing of the coding regions of the FBN1 gene. Reads were compared with the 109 110 RefSeq NG 008805 using the Geneious Prime Software (Biomatters Ltd).

Detailed information on DNA extraction, targeted next-generation sequencing Ion 111 Torrent PGM (Thermo Fisher Scientific), direct Sanger sequencing are provided in the 112 Supplementary Materials and Methods. 113

### 114 Variants classification

# 115

116 The variant call files (VCF) were subjected to a series of filters to exclude benign polymorphisms and intronic variants. These filters selected variants located in exons, splice 117 118 sites, and 3'/5' UTRs with sequencing coverage  $\geq 20x$  and minor allele frequency (MAF) < 0.0005 in the general population (gnomAD, https://gnomad.broadinstitute.org/). Check of 119 strand bias, indels in homopolymer and high frequency in internal samples were applied to 120 detect and exclude false positives (sequencing artifacts). The remaining variants were 121 122 classified according to the criteria set forth by the American College of Medical Genetics and 123 Genomics (ACMG) and updates, and the Clinical Genome Resource (ClinGen) (14-17). 124 Sequencing artifact suspects and clinical relevant variants were confirmed by direct 125 sequencing. Reportable variants in this work were pathogenic variants (PV), likely 126 pathogenic variants (LPV), and variants of uncertain significance (VUS).

127

# 128 **RESULTS**

129

We analyzed 79 individuals with TAD. The majority of patients presented a nonsyndromic vascular phenotype; eight were diagnosed with MFS. Seventy-two patients were tested by tNGS and 7 MFS individuals were submitted to FBN1 direct sequencing screening. No variants were detected in EFEMP2, FOXE3, SMAD2 and TGFBR1. According to ACMG/AMP guidelines for variant classification we defined 5 PV, 5 LPV, and 19 VUS (Table 1 and 2). Sequencing artifacts and likely benign variants were excluded.

The highest incidence of clinically relevant variants was found in the FBN1 gene, with 136 4 PV and 2 LPV (Figure 1), of these the majority of patients had MFS, and two presented 137 138 with isolated aortopathy. The others PV/LPV were found once in each of the following genes: ACTA2, TGFB2R, MYLK, and SMAD3. Overall, there were 2 nonsense variants, four 139 missense variants, two frameshift deletions, and two splice site variants. Six variants have 140 141 been previously reported in association with MFS/TAA or cited in ClinVar database in an aorta disease case. We identified four novel variants in this cohort, of which the truncation 142 143 variant p.Glu2019Ter in FBN1 was recently reported by our group in association with MFS (18). Hereafter, we detail each variant and the ACMG criteria used for pathogenicity 144 145 classification.

146

### 147 **FBN1**

The missense variants in the FBN1 gene, p.Gly560Val and p.Arg1530Cys, were classified as pathogenic and likely pathogenic, respectively. The FBN1 gene is intolerant to missense variants as demonstrated by the gnomAD Z score value (5.06). Regarding missense variants are a common mechanism of pathogenicity for MFS and TAD (19,20), we applied the PP2 criterion to both variants. REVEL (Rare Variant Ensemble Leaner) score was used for in-silico effect prediction of rare missense variants according to Pejaver et al.

(16). The variants p.Gly560Val and p.Arg1530Cys scored 0.945 and 0.871, which fit the PP3\_strong and PP3\_moderate criteria, respectively. Detection of the p.Gly560Val confirmed the clinical diagnosis of SMF of patient AO94. The p.Arg1530Cys variant have been linked to MFS as well as TAD in various publications (21-29), however, the patient AO56, who carries it, experienced an aortic dissection at the age of 38y without an associated syndromic phenotype.

The nonsense variant p.Arg429Ter in FBN1, identified in a female individual with MFS (AO45), is a known PV. Absent in the gnomAD database, the p.Arg429Ter variant has been reported in several individuals with MFS and has been found to segregate with the disease in families (30-34). This supports the application of PM2\_supporting, PS4\_Strong and PP1 criteria. The premature termination codon (PTC) generated by the variant is expected to lead to gene dysfunction through protein truncation or nonsense-mediated mRNA decay, which fills the PVS1 criterion.

167

# 168 **TGFBR2**

The missense variant c.1454G>A (p.Arg485His) in the Transforming Growth Factor-β 169 170 receptor gene (TGFBR2) holds well-established clinical significance, being associated with 171 individuals with SMF, LDS, and familial thoracic aortic dissection in multiple studies (35-40). Despite its high prevalence in affected individuals, the frequency of this variant in gnomAD is 172 173 rare, which supports the application of criteria PS4 and PM2 support, respectively. 174 Additional gnomAD data indicates that the p.Arg485His variant is located in a hotspot region of the TGFBR2 gene, as all 18 VUS/PV described in ClinVar are confined to the region 175 between exon 5 and 8 (PM1). Pannu et al. (36) reported the cosegregation of this variant 176 with the phenotype of familial TAA and dissection with reduced penetrance in two unrelated 177 178 families (PP1). The REVEL score for the p.Arg485His variant is 0.900, in line with the PP3\_moderate criterion. Due to the combined evidence from criteria PS4, PM1, 179 PM2 support, PP1, and PP3 moderate, the p.Arg485His variant is classified as pathogenic. 180

181 The variant was detected in a male patient (AO86) diagnosed at 48y with acute aortic 182 syndrome, extracardiac affections (syndrome not diagnosed) and positive family history of 183 cardiac death.

184

### 185 **SMAD3**

This gene is part of a group of genes recently associated with HTAD (41). The variant at the canonical splicing site (c.872-2A>G) in the SMAD3 gene results in loss of function of the gene product, which is an established mechanism of pathogenicity in SMAD3 (PVS1) (9,42). This variant is absent from gnomAD (PM2\_support) and has a single submission in ClinVar associated with TAA and dissection (PS4\_supporting). This PV (PVS1, PM2\_supporting and PS4\_supporting) was detected in a male patient diagnosed at the age of 35y with a 5.1 cm ascending aortic aneurysm.

193

# 194 **ACTA2**

195 The missense variant p.Arg314Gln (c.941G>A) in the ACTA2 gene has an annotation 196 in ClinVar as a VUS in a TAA case, and is absent in population database (PM2 supporting). The REVEL score of 0.939 indicates the PP3\_strong criterion. The ACTA2 gene is intolerant 197 198 to missense mutations (missense Z score = 3.2), and this type of mutation is a pathogenic mechanism in this gene, which fulfills the PP2 criterion. Due to the combination of 199 PP3\_strong, PM2\_supporting, and PP2 criteria, the variant has been classified as likely 200 pathogenic. The patient carrying this variant is female and has a positive family history. The 201 202 diagnosis of TAA occurred at 48y, with an urgent surgical recommendation.

203

# 204 Novel variants:

205

# 206 **FBN1**

207 The FBN1 variant c.1837+1G>C affects the canonical splicing site critical for proper 208 mRNA processing. In silico evidence from ASSP (Alternative Splice Site Predictor) and 209 Splice AI indicates the loss of the critical donor site, followed exon skipping and truncated 210 product formation (PVS1). The variant has not been reported in the gnomAD or ClinVar 211 databases, neither in any publication (PM2 support). On the other hand, two different variants at the same locus have been associated with fibrilinopathy/SMF (c.1837+1G>T [43]; 212 c.1837+1G>A [44]). Thus, this variant has been classified as pathogenic based on the 213 214 combination of PVS1, PM2 support, and PS1 criteria. This variant was detected in a man diagnosed with ascending aortic dissection at 50y and positive family history of cardiac 215 216 death.

The deletion c.7929\_7930delTG in FBN1 alters the reading frame of the mRNA, resulting in a frameshift and generating a PTC, which is expected to lead to the absence of the gene product through nonsense-mediated decay (NMD) (15). This variant has not yet been reported in any publications or databases (PM2\_support). Therefore, based on the combination of PVS1 and PM2\_support criteria, we classified this variant as likely pathogenic. The patient that harbors this variant is a female with MFS and aortic aneurysm diagnosed at 8y.

224

### 225 **MYLK**

A frameshift deletion c.4848delG in the myosin light chain kinase gene (MYLK) has been classified as likely pathogenic based on the following criteria: PVS1 due to gene loss of function through NMD; PM2\_support due to absence in the gnomAD database. The patient with this variant is male, with a negative family history. He was diagnosed at 60y with TAA, requiring emergency surgery, and presenting with an ascending aorta diameter of 7.3 cm.

- 231
- 232 Diagnosis yield

233

234 PV/LPV were identified in five patients out of 70 individuals with non-syndromic 235 aortopathies resulting in an isolated aortopathy diagnosis rate of 7.1% through tNGS. The 236 diagnostic yield for syndromic aortopathies (8 MFS and 1 undefined syndrome) cases was 55.5%, identifying five patients with PV/LPV. 237

238

### 239 Variants of Uncertain Significance

240

Nineteen VUS were detected in this cohort following the classification of reportable 241 242 variants. Mutations of the following types were observed: missense (11), synonymous (5), 243 one frameshift deletion, and two SNV in UTR. Five variants are novel, and 14 variants have already been reported in ClinVar. The majority of VUS were identified in the FBN1 (7) and 244 MYLK (3) genes, followed by PRKG1 (2), MYH11 (2), and TGFβ2 (2), with one variant in the 245 246 remaining genes: COL3A1, MFAP5, and LOX (Table 2).

Two potentially pathogenic VUS in FBN1 were identified in individuals without 247 248 PV/LPV. These variants did not meet the sufficient criteria for pathogenicity/benignity, due the insufficient available evidences at this time to determine the role of this variation in the 249 250 disease. However, they stand out from other VUS by nearly reaching the required 251 combination for classification as LPV.

The variant p.Asp591Gly is located in the most missense-intolerant region of the 252 253 FBN1 gene (O/E missense: 0.41). It has a low population frequency (0.000003980) in 254 gnomAD database, with only one allele detected in the Latin/Amerindian population. We consider PM2 supporting for MAF<0.002% (45). The REVEL score indicates the PP3 sup 255 criterion. The combination of criteria PM1, PP2, PM2\_sup, and PP3\_sup for this VUS was 256 insufficient to reach a level of pathogenicity. Patient AO42, who carries this mutation, has 257 258 been diagnosed with aortic dissection at 48y and has a positive family history related to 259 cardiac death.

260 The VUS p.lle1455Ser in the FBN1 gene also had only 1 allele found in gnomAD, but 261 it has already been reported in individuals with MFS/TAD in ClinVar and in a publication (46). The REVEL score was compatible with PP3\_mod. The carrier patient (AO88) was primarily 262 263 diagnosed with ascending aortic aneurysm at the age of 58y.

264

#### DISCUSSION 265

266

267 TAD is a silent and highly morbid condition, and a prompt diagnosis and early 268 intervention can save lives (47,48). Therefore, genetic screening becomes a significant tool 269 for early identification, follow-up, and monitoring of high-risk patients, as well as for 270 determining the course of action (48). In this study, a population with a TAD diagnosis age of ≤60 years was selected, given that this age group exhibits a lower incidence of sporadic TAD 271 (49). An average age of early clinical presentation was observed at 44.6y ( $\pm$ 14.3), with a 272

male predominance (63.3%) and 51.9% being of white ethnicity, consistent with observed inother studies (50-52).

275 In the present study, targeted-Next Generation Sequencing (tNGS) was conducted to identify mutations in genes primarily associated with TAD in 71 patients from a tertiary 276 277 cardiology hospital. A total of 29 reportable variants were identified, comprising 5 PV, 5 LPV, and 19 VUS. Among isolated aortopathies, our diagnostic yield was 7.1%. Other studies 278 279 employing tNGS for the investigation of non-syndromic aortopathies reported a diagnostic 280 yield of 4.9% for PV in 1025 patients analyzed (15 sequenced genes) (48) and 16.9% for 281 PV/LPV in 32 genes analyzed (11). Despite the higher yield in the latter work in comparison 282 of our results, SMAD2 was the only additional gene with mutations detected in Thoracic 283 Aortic Aneurysm and Dissection (TAAD) (11).

284 The above studies have shown that the majority of causal variant were detected in 285 the 11 priority genes. The use of Whole Exome Sequencing (WES) in the investigation for 286 aortopathies does not significantly increase the diagnostic yield of TAD, which generally does 287 not reach 20%. Ziganshin et al. (53) performed WES on 102 TAAD patients and found 288 deleterious variants in 3.9% of cases. Meanwhile, Wolford et al. (52) reported a 10.8% 289 diagnostic yield when conducting WES in cases of aortic dissection or rupture. Yang et al. 290 (54) achieved a diagnostic yield for NS-TAD of 18.7% using an investigative strategy that 291 combined tNGS, MLPA, and WES, with WES adding only 3 individuals to the positive 292 diagnosis group.

Initial clinical suspicion is crucial for guiding genetic testing and achieving better diagnostic yield. In this study, patients with a diagnosis or suspicion of MSF were analyzed through direct sequencing of FBN1, resulting in a diagnostic yield of 50%. This yield is higher than that obtained by Renner et al. (11) with a multigene panel (29.8%) and lower than the 83.5% achieved with the combination of targeted Next-Generation Sequencing (tNGS), Multiplex Ligation-dependent Probe Amplification (MLPA), and Whole Exome Sequencing (WES) (53).

Interpreting genetic sequencing data can be challenging due to variants exhibiting inconsistent characteristics for both pathogenicity and benignity (55). A guideline for interpreting genetic variants in aortopathies has not yet been established. Therefore, efforts dedicated to the careful classification of variants identified in patients with TAD can provide significant contributions to the interpretation and molecular diagnosis of these pathologies within the context of precision medicine (56).

Ten PV/LPV were identified in 5 of the 15 analyzed genes (FBN1, ACTA2, TGFBR2, MYLK, and SMAD3), with four of these variants being reported in association with MFS/TAD for the first time in this study. FBN1 had the highest incidence, with six identified variants, following a similar pattern to other studies (57-59). Mutations in FBN1 were initially associated with MFS (60,61); subsequent studies revealed its association with Marfan-like syndromes (45,57). More recent studies have shown FBN1 variants related to NS-TAD, suggesting a common pathogenesis between NS-TAD and MFS (52,59,62). Cysteine

313 substitutions in the calcium-binding of epidermal growth factor (EGF) like domains represent 314 the majority of pathogenic missense changes associated with MFS (63). However, loss of 315 function (LoF) variants were the principal type of variants discovered in our MFS cohort, followed by a glycine to valine substitution in the EGF-like 8 domain. One missense and one 316 317 LoF variant were detected in non-syndromic aortopathies. Haploinsufficiency of fibrillin-1 is a 318 pathogenic mechanism for both MFS (64,65) and NS-TAD (54). Missense mutations can also lead to decreased fibrillin secretion due to improper protein folding (66). In these cases, 319 missense mutations and frameshift LoF mutations would share the haploinsufficiency 320 321 mechanism.

322 FBN1 was also prevalent in VUS (7). Of all VUS, only one (FBN1-p.lle849Met) was 323 found in an individual carrying a PV. On the other hand, two missense VUS identified in 324 individuals with isolated aortopathies have the potential to be upgraded to LPV or PV. One of 325 them (FBN1-p.Asp591Gly) is being reported for the first time in this study. The second VUS 326 has previously been reported as an LPV for MFS (46); however, there is still a lack of 327 evidence in the literature to define its burden. Reporting our findings will contribute to 328 potentially elevating a VUS to a causal variant in the future. Investigating families could 329 provide information lacking for the definitive association of VUS with the disease; 330 unfortunately, we did not have access to the families in this study.

In this study, PV/LPV were also found in the genes ACTA2, TGFBR2, MYLK, and 331 SMAD3, for which gene-disease validity is definitive or strong for familial TAAD. Mutations in 332 333 smooth muscle cell-specific genes (ACTA2, MYLK, MYH11) have been discovered in connection with familial TAAD. This characteristic typically exhibits autosomal dominant 334 inheritance within families, with varying degrees of penetrance and expressivity (67). Actin 335 alpha 2 is a highly conserved protein, and missense variants account for the majority of 336 337 PV/LPV in this gene. The p.Arg314Gln variant is located in exon 7, the only one where no 338 PV/LPV was annotated.

We identified a novel frameshift variant (c.4848delG) in MYLK with the potential to disrupt protein function and result in loss of allele function through NMD. However, at this time, there is limited evidence to support the haploinsufficiency of this gene, given the limited number of TAAD-associated mutations in MYLK in the literature.

Mutations in the TGFBR2 gene have previously been associated with LDS and TAAD in individuals with Marfanoid features (68,69). Patient AO86 exhibited syndromic features reported as EDS type, but without a conclusive diagnosis. The identified variant has a wellestablished association with TAD, with most studies reporting its association with isolated aortopathy. However, Law et al. (37) described carriers of the Arg485His variant with features overlapping EDS type 4 (OMIM 130050), such as soft translucent skin, arthralgia, and varicose veins, which could be considered a distinct syndrome.

This investigation provides a comprehensive insight into aortopathies within a Brazilian cohort, highlighting the genetic diversity inherent in these conditions. The implementation of tNGS yielded a notable diagnostic rate, uncovering PV/LPV in genes

353 associated with aortic diseases. The prevalence of mutations in the FBN1 gene, particularly 354 among patients with both syndromic and non-syndromic Marfan-like features, underscores its 355 clinical significance and underscores the necessity for an individualized approach in managing these cases. Furthermore, the identification of novel variants, whether associated 356 357 with known syndromic phenotypes or not, contributes to the growing understanding of the genetic complexity of aortopathies. These findings underscore the importance of precise 358 genetic screening as a fundamental tool for early intervention and personalized therapeutic 359 360 strategies, paving the way for significant advancements toward precision medicine in the 361 context of aortopathies.

362

# 363 Acknowledgments

- The authors would like to thank the patients enrolled in this study and the support of INC and FAPERJ.
- 366

# 367 Author contributions

**JRF** - Conduction of the work, patient selection and recruitment, clinical evaluation, data collection and analysis, variant analysis, manuscript writing.

- 370 JPP Samples processing and NGS.
- 371 **APAB -** Samples processing and Sanger sequencing.
- 372 **DNA -** Analysis of NGS data and variants interpretation.
- 373 **MMM –** Patients selection and recruitment, supervision of clinical evaluation.
- 374 **HCVR –** Data analysis, study supervision.
- 375 **GMD –** Study idealization, variant analysis, manuscript writing.
- 376

# 377 Declaration of interests

- 378
- The authors declare no competing interests.
- 380

# 381 **REFERENCES**

- 382
- 1. Faggion Vinholo T, Brownstein AJ, Ziganshin BA, Zafar MA, Kuivaniemi H, Body SC, et
- al. Genes Associated with Thoracic Aortic Aneurysm and Dissection: 2019 Update and
   Clinical Implications. Aorta (Stamford). 2019;07(04):099-107.
- Sellke FW, Sellke FW, Coselli JS, Sundt TM, SpringerLink. Aortic dissection and acute
   aortic syndromes. 1st 2021. ed. Cham, Switzerland: Springer Nature Switzerland AG,
   2021. 1 online resource (viii, 659 pages): illustrations p.
- Centers for Disease Control and Prevention (CDC). Data and stats, aortic aneurysms.
   About Multiple Cause of Death, 1999–2019. CDC WONDER Online Database website;
- 391 2021. https://www.cdc.gov/heartdisease/aortic\_aneurysm.htm, Accessed October 19,
- 392 2023.

3934. MS/SVS/CGIAE - Sistema de Informações sobre Mortalidade - SIM. Óbitos p/Residênc394segundoRegião2020[Availablefrom:

- 395 http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sim/cnv/obt10uf.def.
- Oladokun D, Patterson BO, Sobocinski J, Karthikesalingam A, Loftus I, Thompson MM,
   et al. Systematic Review of the Growth Rates and Influencing Factors in Thoracic Aortic
   Aneurysms. Eur J Vasc Endovasc Surg. 2016;51(5):674-81.
- Guo, D. C. Regalado, E. S., Minn, C., Tran-Fadulu, V., Coney, J., Cao, J., Wang, M., Yu,
   R. K., Estrera, A.L., Safi, H. J., Shete, S. S., & Milewicz, D. M. (2011). Familial Thoracic
   Aortic Aneurysms and Dissections. *Circulation: Cardiovascular Genetics*, *4*(1), 36–42.
- Fletcher AJ, Syed MBJ, Aitman TJ, Newby DE, Walker NL. Inherited Thoracic Aortic
  Disease: New Insights and Translational Targets. Circulation. 2020 May
  12;141(19):1570-1587.
- Ahmad MM, Kiani IA, Ammar KA, Ahmad MN, Khandheria BK, Paterick TE, et al.
   Ascending Aortic Aneurysm Is an Inherited Disease: A Contemporary Literature Review
   Based on Hill's Criteria of Specificity, Strength of Association, and Biological Coherence.
   Cardiol Rev. 2017;25(6):268-78.
- Regalado ES, Guo DC, Villamizar C, Avidan N, Gilchrist D, McGillivray B, et al. Exome
   sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm
   and dissection with intracranial and other arterial aneurysms. Circ Res. 2011;109(6):680 6.
- 413 10. Pinard A, Jones GT, Milewicz DM. Genetics of Thoracic and Abdominal Aortic Diseases.
  414 Circ Res. 2019;124(4):588-606.
- 11. Renner S, Schüler H, Alawi M, Kolbe V, Rybczynski M, Woitschach R, Sheikhzadeh S,
  Stark VC, Olfe J, Roser E, Seggewies FS, Mahlmann A, Hempel M, Hartmann MJ,
  Hillebrand M, Wieczorek D, Volk AE, Kloth K, Koch-Hogrebe M, Abou Jamra R, Mitter D,
  Altmüller J, Wey-Fabrizius A, Petersen C, Rau I, Borck G, Kubisch C, Mir TS, von
  Kodolitsch Y, Kutsche K, Rosenberger G. Next-generation sequencing of 32 genes
  associated with hereditary aortopathies and related disorders of connective tissue in a
  cohort of 199 patients. Genet Med. 2019 Aug;21(8):1832-1841.
- 422 12. Verstraeten A, Alaerts M, Van Laer L, Loeys B. Marfan syndrome and related disorders:
  423 25 years of gene discovery. Hum Mutat. 2016;37(6):524-31.
- 13. Renard M, Francis C, Ghosh R, Scott AF, Witmer PD, Adès LC, et al. Clinical Validity of
  Genes for Heritable Thoracic Aortic Aneurysm and Dissection. J Am Coll Cardiol.
  2018;72(6):605-15.
- 427 14. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
  428 guidelines for the interpretation of sequence variants: a joint consensus recommendation
  429 of the American College of Medical Genetics and Genomics and the Association for
  430 Molecular Pathology. Genet Med. 2015;17(5):405-24.
- 431 15. Abou Tayoun et al., Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG, Harrison
   432 SM; ClinGen Sequence Variant Interpretation Working Group (ClinGen SVI).

433 Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant
434 criterion. Hum Mutat. 2018 Nov;39(11):1517-1524.

- 16. Pejaver V, Byrne AB, Feng BJ, Pagel KA, Mooney SD, Karchin R, O'Donnell-Luria A,
  Harrison SM, Tavtigian SV, Greenblatt MS, Biesecker LG, Radivojac P, Brenner SE;
  ClinGen Sequence Variant Interpretation Working Group. Calibration of computational
  tools for missense variant pathogenicity classification and ClinGen recommendations for
  PP3/BP4 criterion. Am J Hum Genet. 2022 Dec 1;109(12):2163-2177.
- Walker LC, de la Hoya M, Wiggins GAR, Lindy A, Vincent LM, Parsons MT, Canson DM,
  Bis-Brewer D, Cass A, Tchourbanov A, Zimmermann H, Byrne AB, Pesaran T, Karam R,
  Harrison S, Spurdle AB. Application of the ACMG/AMP framework to capture evidence
  relevant to predicted and observed impact on splicing: recommendations from the
  clingen svi splicing subgroup. medRxiv [Preprint]. 2023 Feb 26:2023.02.24.23286431.
- 445 Update in: Am J Hum Genet. 2023 Jun
- 18. Pereira JP, Ferreira JR, Botelho APA, Melo MM, Dias GM. Identification of a novel
  pathogenic variant in FBN1 associated with Marfan Syndrome. Cold Spring Harb Mol
  Case Stud. 2022 May 19;8(4):a006215.
- 449 19. Ghosh R, Oak N, Plon SE. Evaluation of in silico algorithms for use with ACMG/AMP
  450 clinical variant interpretation guidelines. Genome Biol. 2017 Nov 28;18(1):225.
- 20. Sakai LY, Keene DR, Renard M, De Backer J. FBN1: The disease-causing gene for
  Marfan syndrome and other genetic disorders. Gene. 2016 Oct 10;591(1):279-291.
- 453 21. Jin C, Yao K, Jiang J, Tang X, Shentu X, Wu R. Novel FBN1 mutations associated with
  454 predominant ectopia lentis and marfanoid habitus in Chinese patients. Mol Vis. 2007 Jul
  455 24; 13:1280-4.
- 456 22. Aragon-Martin JA, Ahnood D, Charteris DG, Saggar A, Nischal KK, Comeglio P,
  457 Chandra A, Child AH, Arno G. Role of ADAMTSL4 mutations in FBN1 mutation-negative
  458 ectopia lentis patients. Hum Mutat. 2010 Aug;31(8):E1622-31.
- 459 23. Biggin A, Holman K, Brett M, Bennetts B, Adès L. Detection of thirty novel FBN1
  460 mutations in patients with Marfan syndrome or a related fibrillinopathy. Hum Mutat. 2004
  461 Jan;23(1):99.
- 462 24. Howarth R, Yearwood C, Harvey JF. Application of dHPLC for mutation detection of the
  463 fibrillin-1 gene for the diagnosis of Marfan syndrome in a National Health Service
  464 Laboratory. Genet Test. 2007 Summer;11(2):146-52.
- 465 25. Loeys B, Nuytinck L, Delvaux I, De Bie S, De Paepe A. Genotype and phenotype
  466 analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because
  467 of suspected Marfan syndrome. Arch Intern Med. 2001 Nov 12;161(20):2447-54.
- 26. Rand-Hendriksen S, Tjeldhorn L, Lundby R, Semb SO, Offstad J, Andersen K, Geiran O,
  Paus B. Search for correlations between FBN1 genotype and complete Ghent
  phenotype in 44 unrelated Norwegian patients with Marfan syndrome. Am J Med Genet
  A. 2007 Sep 1;143A(17):1968-77.

472 27. Villamizar C, Regalado ES, Fadulu VT, Hasham SN, Gupta P, Willing MC, Kuang SQ,

473 Guo D, Muilenburg A, Yee RW, Fan Y, Towbin J, Coselli JS, LeMaire SA, Milewicz DM.

- 474 Paucity of skeletal manifestations in Hispanic families with FBN1 mutations. Eur J Med
- 475 Genet. 2010 Mar-Apr;53(2):80-4.
- Wang WJ, Han P, Zheng J, Hu FY, Zhu Y, Xie JS, Guo J, Zhang Z, Dong J, Zheng GY,
  Cao H, Liu TS, Fu Q, Sun L, Yang BB, Tian XL. Exon 47 skipping of fibrillin-1 leads
  preferentially to cardiovascular defects in patients with thoracic aortic aneurysms and
  dissections. J Mol Med (Berl). 2013 Jan;91(1):37-47.
- 480 29. Yoo EH, Woo H, Ki CS, Lee HJ, Kim DK, Kang IS, Park P, Sung K, Lee CS, Chung TY,
  481 Moon JR, Han H, Lee ST, Kim JW. Clinical and genetic analysis of Korean patients with
  482 Marfan syndrome: possible ethnic differences in clinical manifestation. Clin Genet. 2010
  483 Feb;77(2):177-82.
- 30. Rommel K, Karck M, Haverich A, Schmidtke J, Arslan-Kirchner M. Mutation screening of
  the fibrillin-1 (FBN1) gene in 76 unrelated patients with Marfan syndrome or Marfanoid
  features leads to the identification of 11 novel and three previously reported mutations.
  Hum Mutat. 2002 Nov;20(5):406-7.
- 31. Sakai H, Visser R, Ikegawa S, Ito E, Numabe H, Watanabe Y, Mikami H, Kondoh T,
  Kitoh H, Sugiyama R, Okamoto N, Ogata T, Fodde R, Mizuno S, Takamura K, Egashira
  M, Sasaki N, Watanabe S, Nishimaki S, Takada F, Nagai T, Okada Y, Aoka Y, Yasuda
  K, Iwasa M, Kogaki S, Harada N, Mizuguchi T, Matsumoto N. Comprehensive genetic
  analysis of relevant four genes in 49 patients with Marfan syndrome or Marfan-related
  phenotypes. Am J Med Genet A. 2006 Aug 15;140(16):1719-25.
- 494 32. Attanasio M, Lapini I, Evangelisti L, Lucarini L, Giusti B, Porciani M, Fattori R, Anichini C,
  495 Abbate R, Gensini G, Pepe G. FBN1 mutation screening of patients with Marfan
  496 syndrome and related disorders: detection of 46 novel FBN1 mutations. Clin Genet.
  497 2008 Jul;74(1):39-46.
- 33. Magyar I, Colman D, Arnold E, Baumgartner D, Bottani A, Fokstuen S, Addor MC,
  Berger W, Carrel T, Steinmann B, Mátyás G. Quantitative sequence analysis of FBN1
  premature termination codons provides evidence for incomplete NMD in leukocytes.
  Hum Mutat. 2009 Sep;30(9):1355-64.
- 34. Yang H, Luo M, Chen Q, Fu Y, Zhang J, Qian X, Sun X, Fan Y, Zhou Z, Chang Q.
  Genetic testing of the FBN1 gene in Chinese patients with Marfan/Marfan-like syndrome.
  Clin Chim Acta. 2016 Aug 1;459:30-35.
- 35. Disabella E, Grasso M, Marziliano N, Ansaldi S, Lucchelli C, Porcu E, Tagliani M, Pilotto
  A, Diegoli M, Lanzarini L, Malattia C, Pelliccia A, Ficcadenti A, Gabrielli O, Arbustini E.
  Two novel and one known mutation of the TGFBR2 gene in Marfan syndrome not
  associated with FBN1 gene defects. Eur J Hum Genet. 2006 Jan;14(1):34-8.
- 36. Pannu H, Fadulu VT, Chang J, Lafont A, Hasham SN, Sparks E, Giampietro PF, Zaleski
  C, Estrera AL, Safi HJ, Shete S, Willing MC, Raman CS, Milewicz DM. Mutations in

transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms
 and dissections. Circulation. 2005 Jul 26;112(4):513-20.

- 37. Law C, Bunyan D, Castle B, Day L, Simpson I, Westwood G, Keeton B. Clinical features
  in a family with an R460H mutation in transforming growth factor beta receptor 2 gene. J
  Med Genet. 2006 Dec;43(12):908-16.
- 38. Campens L, Callewaert B, Muiño Mosquera L, Renard M, Symoens S, De Paepe A,
  Coucke P, De Backer J. Gene panel sequencing in heritable thoracic aortic disorders
  and related entities results of comprehensive testing in a cohort of 264 patients.
  Orphanet J Rare Dis. 2015 Feb 3;10:9.
- 39. Singh KK, Rommel K, Mishra A, Karck M, Haverich A, Schmidtke J, Arslan-Kirchner M.
  TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and
  Loeys-Dietz syndrome. Hum Mutat. 2006 Aug;27(8):770-7.
- 40. Guerrerio AL, Frischmeyer-Guerrerio PA, Huang C, Wu Y, Haritunians T, McGovern
  DPB, MacCarrick GL, Brant SR, Dietz HC. Increased Prevalence of Inflammatory Bowel
  Disease in Patients with Mutations in Genes Encoding the Receptor Subunits for TGFβ.
  Inflamm Bowel Dis. 2016 Sep;22(9):2058-2062.
- 41. Takeda N, Komuro I. Genetic basis of hereditary thoracic aortic aneurysms and
  dissections. J Cardiol. 2019 Aug;74(2):136-143.
- 42. Aubart M, Gobert D, Aubart-Cohen F, Detaint D, Hanna N, d'Indya H, Lequintrec JS,
  Renard P, Vigneron AM, Dieudé P, Laissy JP, Koch P, Muti C, Roume J, Cusin V,
  Grandchamp B, Gouya L, LeGuern E, Papo T, Boileau C, Jondeau G. Early-onset
  osteoarthritis, Charcot-Marie-Tooth like neuropathy, autoimmune features, multiple
  arterial aneurysms and dissections: an unrecognized and life threatening condition.
  PLoS One. 2014 May 7;9(5):e96387.
- 535 43. Stheneur C, Collod-Béroud G, Faivre L, Buyck JF, Gouya L, Le Parc JM, Moura B, Muti
  536 C, Grandchamp B, Sultan G, Claustres M, Aegerter P, Chevallier B, Jondeau G, Boileau
  537 C. Identification of the minimal combination of clinical features in probands for efficient
  538 mutation detection in the FBN1 gene. Eur J Hum Genet. 2009 Sep;17(9):1121-8.
- 44. Loeys B, De Backer J, Van Acker P, Wettinck K, Pals G, Nuytinck L, Coucke P, De
  Paepe A. Comprehensive molecular screening of the FBN1 gene favors locus
  homogeneity of classical Marfan syndrome. Hum Mutat. 2004 Aug;24(2):140-6.
- 45. Harrison SM, Biesecker LG, Rehm HL. Overview of Specifications to the ACMG/AMP
  Variant Interpretation Guidelines. Curr Protoc Hum Genet. 2019 Sep;103(1):e93.
- 46. Lerner-Ellis JP, Aldubayan SH, Hernandez AL, Kelly MA, Stuenkel AJ, Walsh J, Joshi
  VA. The spectrum of FBN1, TGFβR1, TGFβR2 and ACTA2 variants in 594 individuals
  with suspected Marfan Syndrome, Loeys-Dietz Syndrome or Thoracic Aortic Aneurysms
  and Dissections (TAAD). Mol Genet Metab. 2014 Jun;112(2):171-6.
- 47. Johansson G, Markstrom U, Swedenborg J. Ruptured thoracic aortic aneurysms: a study
  of incidence and mortality rates. J Vasc Surg. 1995;21(6):985-8.

48. Weerakkody R, Ross D, Parry DA, Ziganshin B, Vandrovcova J, Gampawar P, Abdullah
A, Biggs J, Dumfarth J, Ibrahim Y; Yale Aortic Institute Data and Repository Team;
Bicknell C, Field M, Elefteriades J, Cheshire N, Aitman TJ. Targeted genetic analysis in
a large cohort of familial and sporadic cases of aneurysm or dissection of the thoracic
aorta. Genet Med. 2018 Nov;20(11):1414-1422.

- 555 49. Isselbacher EM, Preventza O, Hamilton Black J 3rd, Augoustides JG, Beck AW, Bolen 556 MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, Collins TJ, DeAnda A 557 Jr, Fanola CL, Girardi LN, Hicks CW, Hui DS, Schuyler Jones W, Kalahasti V, Kim KM, Milewicz DM, Oderich GS, Ogbechie L, Promes SB, Gyang Ross E, Schermerhorn ML, 558 Singleton Times S, Tseng EE, Wang GJ, Woo YJ. 2022 ACC/AHA Guideline for the 559 Diagnosis and Management of Aortic Disease: A Report of the American Heart 560 Association/American College of Cardiology Joint Committee on Clinical Practice 561 Guidelines. Circulation. 2022 Dec 13;146(24):e334-e482. 562
- 563 50. Trimarchi S, Nienaber CA, Rampoldi V, Myrmel T, Suzuki T, Mehta RH, et al.
  564 Contemporary results of surgery in acute type A aortic dissection: The International
  565 Registry of Acute Aortic Dissection experience. J Thorac Cardiovasc Surg.
  566 2005;129(1):112-22.
- 567 51. Sherrah AG, Andvik S, van der Linde D, Davies L, Bannon PG, Padang R, et al.
  568 Nonsyndromic Thoracic Aortic Aneurysm and Dissection: Outcomes With Marfan
  569 Syndrome Versus Bicuspid Aortic Valve Aneurysm. J Am Coll Cardiol. 2016;67(6):618570 26.
- 52. Wolford BN, Hornsby WE, Guo D, Zhou W, Lin M, Farhat L, et al. Clinical Implications of
  Identifying Pathogenic Variants in Individuals With Thoracic Aortic Dissection. Circ
  Genom Precis Med. 2019;12(6):e002476.
- 574 53. Ziganshin BA, Bailey AE, Coons C, Dykas D, Charilaou P, Tanriverdi LH, et al. Routine
  575 Genetic Testing for Thoracic Aortic Aneurysm and Dissection in a Clinical Setting. Ann
  576 Thorac Surg. 2015;100(5):1604-11.
- 54. Yang H, Shen H, Zhu G, Shao X, Chen Q, Yang F, Zhang Y, Zhang Y, Zhao K, Luo M,
  Zhou Z, Shu C. Molecular characterization and clinical investigation of patients with
  heritable thoracic aortic aneurysm and dissection. J Thorac Cardiovasc Surg. 2022 Nov
  12:S0022-5223(22)01234-X.
- 55. Koboldt, D.C. Best practices for variant calling in clinical sequencing. *Genome Med* 12,
  91 (2020).
- 56. Ponińska JK, Bilińska ZT, Truszkowska G, Michalak E, Podgórska A, Stępień-Wojno M,
  Chmielewski P, Lutyńska A, Płoski R. Good performance of the criteria of American
  College of Medical Genetics and Genomics/Association for Molecular Pathology in
  prediction of pathogenicity of genetic variants causing thoracic aortic aneurysms and
  dissections. J Transl Med. 2022 Jan 25;20(1):42.

57. Wooderchak-Donahue W, VanSant-Webb C, Tvrdik T, Plant P, Lewis T, Stocks J, et al. Clinical utility of a next generation sequencing panel assay for Marfan and Marfan-like syndromes featuring aortopathy. Am J Med Genet A. 2015;167A(8):1747-57.

- 58. Poninska JK, Bilinska ZT, Franaszczyk M, Michalak E, Rydzanicz M, Szpakowski E, et
  al. Next-generation sequencing for diagnosis of thoracic aortic aneurysms and
  dissections: diagnostic yield, novel mutations and genotype phenotype correlations. J
  Transl Med. 2016;14(1):115.
- 595 59. Proost D, Vandeweyer G, Meester JA, Salemink S, Kempers M, Ingram C, et al.
  596 Performant mutation identification using targeted next-generation sequencing of 14
  597 thoracic aortic aneurysm genes. Hum Mutat. 2015;36(8):808-14.
- 598 60. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan
  599 syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature.
  600 1991;352(6333):337-9.
- 601 61. Maslen CL, Corson GM, Maddox BK, Glanville RW, Sakai LY. Partial sequence of a 602 candidate gene for the Marfan syndrome. Nature. 1991;352(6333):334-7.
- 603 62. Fang M, Yu C, Chen S, Xiong W, Li X, Zeng R, et al. Identification of Novel Clinically
  604 Relevant Variants in 70 Southern Chinese patients with Thoracic Aortic Aneurysm and
  605 Dissection by Next-generation Sequencing. Sci Rep. 2017;7(1):10035.
- 606 63. Collod-Béroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M, Child A,
  607 Comeglio P, De Paepe A, Hyland JC, Holman K, Kaitila I, Loeys B, Mátyás G, Nuytinck
  608 L, Peltonen L, Rantamaki T, Robinson P, Steinmann B, Junien C, Béroud C, Boileau C.
  609 Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism
  610 database. Hum Mutat. 2003 Sep;22(3):199-208.
- 64. Mátyás G, Alonso S, Patrignani A, Marti M, Arnold E, Magyar I, Henggeler C, Carrel T,
  Steinmann B, Berger W. Large genomic fibrillin-1 (FBN1) gene deletions provide
  evidence for true haploinsufficiency in Marfan syndrome. Hum Genet. 2007
  Aug;122(1):23-32.
- 65. Li J, Wu W, Lu C, Liu Y, Wang R, Si N, Liu F, Zhou J, Zhang S, Zhang X. Gross
  deletions in FBN1 results in variable phenotypes of Marfan syndrome. Clin Chim Acta.
  2017 Nov;474:54-59.
- 66. Whiteman P, Hutchinson S, Handford PA. Fibrillin-1 misfolding and disease. Antioxid
  Redox Signal. 2006;8:338–346.
- 67. Albornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA, Elefteriades JA.
  Familial thoracic aortic aneurysms and dissections--incidence, modes of inheritance, and
  phenotypic patterns. Ann Thorac Surg. 2006 Oct;82(4):1400-5.
- 623 68. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular,
  624 craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1
  625 or TGFBR2. Nat Genet. 2005;37:275–281.

- 69. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in 626
- Marfan syndrome. Nat Genet. 2004;36:855-860. 627

### **FIGURE LEGEND** 628

629

630

631 Figure 1 - Structure of the FBN1 gene representing the respective domains of the fibrillin-1 632 protein. The six VP/VPP identified in the FBN1 gene are pointed. EGF: epidermal growth 633 factor-like domains; cb-EGF: EGF-like domains with a calcium-binding domain; TB domain: 634 domains similar to TGF-b binding proteins; hybrid: hybrid containing characteristics of the TB 635 and cb-EGF domains

636

TABLES 637

### Table 1. Pathogenic and likely pathogenic variants

ID	Phenotype	Gene	Locus	Transcript	Genotype	Туре	Protein impact	Exon	MAF	ACMG Criteria
AO45 <sup>a</sup>	MFS	FBN1	chr15:48808422	NM_000138.5	c.1285C>T	Nonsense	p.Arg429Ter	11	NR	<b>Pathogenic</b> PVS1, PS4_str <sup>b</sup> , PM2_sup, PP1 <sup>c</sup> , PP4
AO56	Ao dissection	FBN1	chr15:48760294	NM_000138.5	c.4588C>T	Missense	p.Arg1530Cys	38	NR	<b>Likely Pathogenic</b> PS4_mod <sup>d</sup> , PM2_sup, PP1, PP2, PP3_mod
AO71 <sup>ª</sup>	MFS	FBN1	chr15:48734026	NM_000138.5	c.6055G>T	Nonsense	p.Glu2019Ter	50	NR	Pathogenic PVS1, PM2_sup, PM6 <sup>°</sup> , PP1, PP4
AO84	Ao dissection	FBN1	chr15:48800778	NM_000138.5	c.1837+1G>C	Sítio de splice	p.?	15	NR	Pathogenic PVS1_str, PS1 <sup>f</sup> , PM2_sup
AO85	Ao dissection	ACTA2	chr10:90697867	NM_001613.4	c.941G>A	Missense	p.Arg314Gln	8	NR	Likely Pathogenic PP3_str, PM2_sup, PP2
AO86	Ao dissection/EC	TGFBR2	chr3:30715721	NM_001024847.2	c.1454G>A	Missense	p.Arg485His	6	0.000004	<b>Pathogenic</b> PS4 <sup>g</sup> , PM2_sup, PM5, PP3_mod, PP1_str <sup>h</sup>
AO87 <sup>ª</sup>	MFS	FBN1	chr15:48707855	NM_000138.5	c.7929_7930delTG	Del-Frameshift	p.Ser2643ArgfsTer8	64	NR	Likely Pathogenic PVS1, PM2_sup
AO92	Ao dissection	MYLK	chr3:123357030	NM_053025.4	c.4848delG	Del-Frameshift	p.Ser1617LeufsTer2	29	NR	Likely Pathogenic PVS1,PM2_sup
AO94 <sup>ª</sup>	MFS	FBN1	chr15:48802276	NM_000138.5	c.1679G>T	Missense	p.Gly560Val	14	NR	<b>Pathogenic</b> PS4_sup <sup>i</sup> , PM1, PM2_sup, PP2, PP3_str, PP4
AO99	Ao aneurysm	SMAD3	chr15:67477063	NM_005902.4	c.872-2A>G	Sítio de splice	p.?	7	NR	Likely Pathogenic PVS1_str, PS4_sup <sup>i</sup> , PM2_sup

ACMG, American College of Medical Genetic and Genomic; ID, subject identification; MAF, minor allele frequency in gnomAD; NR, not reported; EC, extracardiac affections; str, strong; mod, moderate; sup, supporting

<sup>a</sup>FBN1 direct sequencing approach

<sup>b</sup>Variant reported in several people with MFS (PMID: 12402346, 18435798, 16835936, 27234404, 19618372)

<sup>c</sup>Variant reported cosegregation with disease in affected family members (PMID: 12402346, 16835936, 18435798)

<sup>d</sup>Variant associated with SMF in 5 non-related people (PMID: 14695540, 17627385, 17663468, 11700157)

<sup>e</sup>Parents are not variant carriers without paternity confirmation

<sup>f</sup>Pathogenic variants with another nucleotide exchange at the same splice site +-1,2 (c.1837+1G>A/T, PMID: 19293843, 15241795)

<sup>g</sup>Variant reported in several people with aortopathies (PMID: 16027248, 16885183, 25644172, 27508510, 23884466, 18852674)

<sup>h</sup>Variant segregates with aortopathies in some families (PMID: 16027248, 16885183)

<sup>i</sup>Variant reported in 2 MFS individuals in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/803096/) <sup>j</sup>Variant reported in 1 MFS individuals in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/1968962/)

# Table 2. Variants of uncertain significance

ID	Phenotype	Gene	Locus	Transcript	Genotype	Protein impact	Exon	dbSNP	MAF	ACMG Criteria
AO12	Ao aneurysm	PRKG1	chr10:53814273	NM_006258.4	c.792C>T	p.lle264=	6	rs1165873275	0.000003983	PM2_sup, BP4
AO32	Ao aneurysm	TGFB2	chr1:218519941	NM_001135599.3	c97delA	p.?	1	NR	NR	PM2_sup
AO37	Ao dissection	FBN1	chr15:48703095	NM_000138.5	c.*92T>C	p.?	66	rs1038325459	NR	PM2_sup
AO40	Ao aneurysm	MYH11	chr16:15815483	NM_001040114.1	c.4395C>G	p.Ala1465=	33	NR	NR	PM2_sup, BP4, BP7
AO42	Ao dissection	FBN1	chr15:48800844	NM_000138.5	c.1772A>G	p.Asp591Gly	15	rs1380921125	0.000003980	PM1, PM2_sup, PP2, PP3_sup
AO44	Ao aneurysm	MYLK	chr3:123471182	NM_053025.4	c.369A>T	p.Val123=	5	rs746517311	0.000003982	PM2_sup, BP7
A045 <sup>ª</sup>	Ao dissection	FBN1	chr15:48787450	NM_000138.5	c.2547C>G	p.lle849Met	22	rs778258207	0.00003581	PP2, PP4, BP4_mod
AO48	Ao dissection	FBN1	chr15:48808442	NM_000138.5	c.1265G>A	p.Gly422Glu	11	rs139968089	0.00008139	PP2
AO55	Ao dissection	MYH11	chr16:15810999	NM_001040114.1	c.5523C>T	p.Ala1841=	39	NR	NR	PM2_sup, BP4, BP7
AO58	Ao dissection	COL3A1	chr2:189856420	NM_000090.4	c.923G>A	p.Arg308Gln	13	rs753589858	0.00001592	PM2_sup, PP2
AO60	Ao aneurysm	MYLK	chr3:123348391	NM_053025.4	c.5044G>A	p.Asp1682Asn	30	rs140456660	0.00001591	PM1, PM2_sup
AO69	Ao aneurysm	MFAP5	chr12:8800764	NM_003480.4	c.444delT	p.Arg149GlyfsTer28	10	rs756582294	0.00002388	PVS1_sup
AO72	Ao aneurysm	PRKG1	chr10:53814271	NM_006258.4	c.790A>G	p.lle264Val	6	rs56082459	0.00009559	BS1
AO83	Ao dissection	FBN1	chr15:48714264	NM_000138.5	c.7455T>G	p.Asp2485Glu	61	rs377272529	0.00004603	PM5, PP3_sup
AO88	Ao aneurysm	FBN1	chr15:48762926	NM_000138.5	c.4364T>G	p.lle1455Ser	36	rs397515807	0.000003980	PP3_mod, PS4_sup, PM2_sup, PP2
		LOX	chr5:121412658	NM_002317.7	c.670G>C	p.Ala224Pro	2	rs1282574280	NR	PM2_sup
AO95	Ao dissection	MYLK	chr3:123427680	NM_053025.4	c.2005T>G	p.Phe669Val	15	rs755957947	0.00004596	none
AO96	Ao aneurysm	FBN1	chr15:48725102	NM_000138.5	c.6700G>A	p.Val2234Met	55	rs112084407	0.0007400	PP2, BS1, BP4_sup
AO99	Ao aneurysm	TGFB2	chr1:218607783	NM_001135599.3	c.831A>G	p.Arg277=	5	rs147960792	0.00009245	none

ACMG, American College of Medical Genetic and Genomic; ID, subject identification; MAF, minor allele frequency in gnomAD; NR, not reported; EC, extracardiac affections; str, strong; mod, moderate; sup, supporting

<sup>a</sup>FBN1 direct sequencing approach

